PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-116.92%
Negative EBIT growth while AXSM is at 23.84%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-185.87%
Negative operating income growth while AXSM is at 35.57%. Joel Greenblatt would press for urgent turnaround measures.
-92.79%
Negative net income growth while AXSM stands at 19.26%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-3998.91%
Negative EPS growth while AXSM is at 20.49%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-3998.91%
Negative diluted EPS growth while AXSM is at 20.49%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-95.29%
Share reduction while AXSM is at 1.17%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-95.29%
Reduced diluted shares while AXSM is at 1.17%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
75.47%
OCF growth above 1.5x AXSM's 25.25%. David Dodd would confirm a clear edge in underlying cash generation.
66.24%
FCF growth above 1.5x AXSM's 25.25%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-141.36%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-420.27%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-362.87%
Negative 3Y OCF/share CAGR while AXSM stands at 23.58%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-427041.90%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-659606.65%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-1088784.48%
Negative 3Y CAGR while AXSM is 11.48%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
-4964.64%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-1566.95%
Negative 3Y equity/share growth while AXSM is at 280.02%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1993307.75%
Asset growth above 1.5x AXSM's 7.23%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
57821.37%
BV/share growth above 1.5x AXSM's 35.76%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
2.24%
Debt growth far above AXSM's 2.81%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
178.96%
R&D growth drastically higher vs. AXSM's 10.62%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
203.49%
SG&A growth well above AXSM's 7.86%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.